Ack family non-receptor tyrosine kinases are unique with regard to their domain composition and regulatory properties. Human Ack1 (activated Cdc42-associated kinase) is ubiquitously expressed and is activated by signals that include growth factors and integrin-mediated cell adhesion. Stimulation leads to Ack1 autophosphorylation and to phosphorylation of additional residues in the C-terminus. The N-terminal SAM domain is required for full activation. Ack1 exerts some of its effects via protein-protein interactions that are independent of its kinase activity. In the basal state, Ack1 activity is suppressed by an intramolecular interaction between the catalytic domain and the C-terminal region. Inappropriate Ack1 activation and signaling has been implicated in the development, progression, and metastasis of several forms of cancer. Thus, there is increasing interest in Ack1 as a drug target, and studies of the regulatory properties of the enzyme may reveal features that can be exploited in inhibitor design. 1. Introduction The mammalian nonreceptor tyrosine kinases (NRTKs) are divided into ten families: Src, Abl, Jak, Ack, Csk, Fak, Fes, Frk, Tec, and Syk [1]. In addition to their tyrosine kinase catalytic domains, they all contain noncatalytic domains that are important in enzyme regulation and substrate recognition [2]. Like all eukaryotic protein kinases, NRTK catalytic domains have an N-terminal lobe (N-lobe) that contacts ATP, and a larger C-terminal lobe (C-lobe). The activation state of the tyrosine kinases depends on the orientation of an alpha helix (αC) located in the N-lobe. In the active conformation, the αC helix projects inward toward the ATP-binding site [3]. The conformation of a flexible segment in the C-lobe (the activation loop) also has a key role in the regulation of the enzyme activity [4]. The regulatory importance of the phosphorylation of the activation loop varies in the different families of NRTKs. For instance, Src activation is strongly dependent on autophosphorylation [5], while Csk lacks the autophosphorylation site [6]. The contributions of the noncatalytic domains to enzyme regulation are well understood in the case of the Src-family of NRTKS. These enzymes have an N-terminal myristoylation site followed by an SH3 domain, an SH2 domain, and a kinase domain. Two tyrosine residues are important for their activity: Tyr 416 in the activation loop and Tyr 527 in the C-terminal tail. Structural studies showed the spatial arrangement of Src domains in the inactive state, in which the noncatalytic domains mediate intramolecular
References
[1]
P. Blume-Jensen and T. Hunter, “Oncogenic kinase signalling,” Nature, vol. 411, no. 6835, pp. 355–365, 2001.
[2]
W. T. Miller, “Determinants of substrate recognition in nonreceptor tyrosine kinases,” Accounts of Chemical Research, vol. 36, no. 6, pp. 393–400, 2003.
[3]
T. Pawson and M. Kofler, “Kinome signaling through regulated protein-protein interactions in normal and cancer cells,” Current Opinion in Cell Biology, vol. 21, no. 2, pp. 147–153, 2009.
[4]
S. R. Hubbard and J. H. Till, “Protein tyrosine kinase structure and function,” Annual Review of Biochemistry, vol. 69, pp. 373–398, 2000.
[5]
J. M. Bradshaw, “The Src, Syk, and Tec family kinases: distinct types of molecular switches,” Cellular Signalling, vol. 22, no. 8, pp. 1175–1184, 2010.
[6]
E. T. Mikkola and C. G. Gahmberg, “Hydrophobic interaction between the SH2 Domain and the Kinase Domain is required for the activation of Csk,” Journal of Molecular Biology, vol. 399, no. 4, pp. 618–627, 2010.
[7]
F. Sicheri, I. Moarefi, and J. Kuriyan, “Crystal structure of the Src family tyrosine kinase Hck,” Nature, vol. 385, no. 6617, pp. 602–609, 1997.
[8]
W. Xu, S. C. Harrison, and M. J. Eck, “Three-dimensional structure of the tyrosine kinase c-Src,” Nature, vol. 385, no. 6617, pp. 595–602, 1997.
[9]
I. Moarefi, M. LaFevre-Bernt, F. Sicheri et al., “Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement,” Nature, vol. 385, no. 6617, pp. 650–653, 1997.
[10]
J. A. Cooper and C. S. King, “Dephosphorylation or antibody binding to the carboxy terminus stimulates pp60(c-src),” Molecular and Cellular Biology, vol. 6, no. 12, pp. 4467–4477, 1986.
[11]
M. Porter, T. Schindler, J. Kuriyan, and W. T. Miller, “Reciprocal regulation of Hck activity by phosphorylation of Tyr and Tyr: effect of introducing a high affinity intramolecular SH2 ligand,” Journal of Biological Chemistry, vol. 275, no. 4, pp. 2721–2726, 2000.
[12]
P. Pellicena and W. T. Miller, “Coupling kinase activation to substrate recognition in SRC-family tyrosine kinases,” Front Biosci, vol. 7, pp. d256–267, 2002.
[13]
H. Qiu and W. T. Miller, “Role of the Brk SH3 domain in substrate recognition,” Oncogene, vol. 23, no. 12, pp. 2216–2223, 2004.
[14]
O. Hantschel and G. Superti-Furga, “Regulation of the c-Abl and Bcr-Abl tyrosine kinases,” Nature Reviews Molecular Cell Biology, vol. 5, no. 1, pp. 33–44, 2004.
[15]
E. T. Mikkola and M. Bergman, “Conserved hydrophobicity in the SH2-kinase linker is required for catalytic activity of Csk and CHK,” FEBS Letters, vol. 544, no. 1–3, pp. 11–14, 2003.
[16]
A. Ogawa, Y. Takayama, H. Sakai et al., “Structure of the carboxyl-terminal Src kinase, Csk,” Journal of Biological Chemistry, vol. 277, no. 17, pp. 14351–14354, 2002.
[17]
S. Takeuchi, Y. Takayama, A. Ogawa, K. Tamura, and M. Okada, “Transmembrane phosphoprotein Cbp positively regulates the activity of the carboxyl-terminal Src kinase, Csk,” Journal of Biological Chemistry, vol. 275, no. 38, pp. 29183–29186, 2000.
[18]
M. L. Galisteo, Y. Yang, J. Ure？a, and J. Schlessinger, “Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 26, pp. 9796–9801, 2006.
[19]
E. Manser, T. Leung, H. Salihuddin, L. Tan, and L. Lim, “A non-receptor tyrosine kinase that inhibits the GTPase activity of p21(cdc42),” Nature, vol. 363, no. 6427, pp. 364–367, 1993.
[20]
M. Teo, L. Tan, L. Lim, and E. Manser, “The tyrosine kinase ACK1 associates with clathrin-coated vesicles through a binding motif shared by arrestin and other adaptors,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 18392–18398, 2001.
[21]
F. Shen, Q. Lin, Y. Gu, C. Childress, and W. Yang, “Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation,” Molecular Biology of the Cell, vol. 18, no. 3, pp. 732–742, 2007.
[22]
X. Zhang, K. A. Pickin, R. Bose, N. Jura, P. A. Cole, and J. Kuriyan, “Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface,” Nature, vol. 450, no. 7170, pp. 741–744, 2007.
[23]
N. A. Hopper, J. Lee, and P. W. Sternberg, “ARK-1 inhibits EGFR signaling in C. elegans,” Molecular Cell, vol. 6, no. 1, pp. 65–75, 2000.
[24]
K. P. Sem, B. Zahedi, I. Tan, M. Deak, L. Lim, and N. Harden, “ACK family tyrosine kinase activity is a component of Dcdc42 signaling during dorsal closure in Drosophila melanogaster,” Molecular and Cellular Biology, vol. 22, no. 11, pp. 3685–3697, 2002.
[25]
E. H. Van Der Horst, Y. Y. Degenhardt, A. Strelow et al., “Metastatic properties and genomic amplification of the tyrosine kinase gene ACK1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 44, pp. 15901–15906, 2005.
[26]
G. T. Hoehn, T. Stokland, S. Amin et al., “Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34/Lin/CD38 stem/progenitor cells,” Oncogene, vol. 12, no. 4, pp. 903–913, 1996.
[27]
K. Hoare, S. Hoare, O. M. Smith, G. Kalmaz, D. Small, and W. S. May, “Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling,” Oncogene, vol. 22, no. 23, pp. 3562–3577, 2003.
[28]
D. M. Felschow, C. I. Civin, and G. T. Hoehn, “Characterization of the tyrosine kinase Tnk1 and its binding with phospholipase C-γ1,” Biochemical and Biophysical Research Communications, vol. 273, no. 1, pp. 294–301, 2000.
[29]
N. Azoitei, A. Brey, T. Busch, S. Fulda, G. Adler, and T. Seufferlein, “Thirty-eight-negative kinase 1 (TNK1) facilitates TNFα-induced apoptosis by blocking NF-κB activation,” Oncogene, vol. 26, no. 45, pp. 6536–6545, 2007.
[30]
S. Hoare, K. Hoare, M. K. Reinhard, Y. J. Lee, S. P. Oh, and W. S. May, “Tnk1/Kos1 knockout mice develop spontaneous tumors,” Cancer Research, vol. 68, no. 21, pp. 8723–8732, 2008.
[31]
W. Yang and R. A. Cerione, “Cloning and characterization of a novel Cdc42-associated tyrosine kinase, ACK-2, from bovine brain,” Journal of Biological Chemistry, vol. 272, no. 40, pp. 24819–24824, 1997.
[32]
G. Manning, D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam, “The protein kinase complement of the human genome,” Science, vol. 298, no. 5600, pp. 1912–1934, 2002.
[33]
D. R. Robinson, Y. M. Wu, and S. F. Lin, “The protein tyrosine kinase family of the human genome,” Oncogene, vol. 19, no. 49, pp. 5548–5557, 2000.
[34]
D. A. Linseman, K. A. Heidenreich, and S. K. Fisher, “Stimulation of M muscarinic receptors induces phosphorylation of the Cdc42 effector activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway,” Journal of Biological Chemistry, vol. 276, no. 8, pp. 5622–5628, 2001.
[35]
K. Modzelewska, L. P. Newman, R. Desai, and P. J. Keely, “Ack1 mediates Cdc42-dependent cell migration and signaling to p130,” Journal of Biological Chemistry, vol. 281, no. 49, pp. 37527–37535, 2006.
[36]
W. Yang, Q. Lin, J. L. Guan, and R. A. Cerione, “Activation of the Cdc42-associated tyrosine kinase-2 (ACK-2) by cell adhesion via integrin β,” Journal of Biological Chemistry, vol. 274, no. 13, pp. 8524–8530, 1999.
[37]
J. Kato-Stankiewicz, S. Ueda, T. Kataoka, Y. Kaziro, and T. Satoh, “Epidermal growth factor stimulation of the ACK1/Dbl pathway in a Cdc42 and Grb2-dependent manner,” Biochemical and Biophysical Research Communications, vol. 284, no. 2, pp. 470–477, 2001.
[38]
N. Yokoyama and W. T. Miller, “Biochemical properties of the Cdc42-associated tyrosine kinase ACK1. Substrate specificity, autophosphorylation, and interaction with Hck,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 47713–47723, 2003.
[39]
L. Pao-Chun, P. M. Chan, W. Chan, and ED. Manser, “Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases is mediated by Grb2: an analysis of ACK1 effects on Axl signaling,” Journal of Biological Chemistry, vol. 284, no. 50, pp. 34954–34963, 2009.
[40]
K. M. Eisenmann, J. B. McCarthy, M. A. Simpson et al., “Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130,” Nature Cell Biology, vol. 1, no. 8, pp. 507–513, 1999.
[41]
M. Coon and R. Herrera, “Modulation of HeLa cells spreading by the non-receptor tyrosine kinase ACK-2,” Journal of Cellular Biochemistry, vol. 84, no. 4, pp. 655–665, 2002.
[42]
W. Yang, C. G. Lo, T. Dispenza, and R. A. Cerione, “The Cdc42 target ACK2 directly interacts with clathrin and influences clathrin assembly,” Journal of Biological Chemistry, vol. 276, no. 20, pp. 17468–17473, 2001.
[43]
C. Childress, Q. Lin, and W. Yang, “Dimerization is required for SH3PX1 tyrosine phosphorylation in response to epidermal growth factor signalling and interaction with ACK2,” Biochemical Journal, vol. 394, no. 3, pp. 693–698, 2006.
[44]
L. Yeow-Fong, L. Lim, and ED. Manser, “SNX9 as an adaptor for linking synaptojanin-1 to the Cdc42 effector ACK1,” FEBS Letters, vol. 579, no. 22, pp. 5040–5048, 2005.
[45]
L. M. Gr？vdal, L. E. Johannessen, M. S. R？dland, I. H. Madshus, and E. Stang, “Dysregulation of Ack1 inhibits down-regulation of the EGF receptor,” Experimental Cell Research, vol. 314, no. 6, pp. 1292–1300, 2008.
[46]
B. T. Chua, S. J. Lim, S. C. Tham, W. J. Poh, and A. Ullrich, “Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells,” Molecular Oncology, vol. 4, no. 4, pp. 323–334, 2010.
[47]
J. Howlin, J. Rosenkvist, and T. Andersson, “TNK2 preserves epidermal growth factor receptor expression on the cell surface and enhances migration and invasion of human breast cancer cells,” Breast Cancer Research, vol. 10, no. 2, p. R36, 2008.
[48]
Q. Lin, C. G. Lo, R. A. Cerione, and W. Yang, “The Cdc42 target ACK2 interacts with sorting nexin 9 (SH3PX1) to regulate epidermal growth factor receptor degradation,” Journal of Biological Chemistry, vol. 277, no. 12, pp. 10134–10138, 2002.
[49]
W. Chan, R. Tian, Y. F. Lee, S. T. Sit, L. Lim, and ED. Manser, “Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2,” Journal of Biological Chemistry, vol. 284, no. 12, pp. 8185–8194, 2009.
[50]
Q. Lin, J. Wang, C. Childress, M. Sudol, D. J. Carey, and W. Yang, “HECT E3 ubiquitin ligase Nedd4-1 ubiquitinates ACK and regulates epidermal growth factor (EGF)-induced degradation of EGF receptor and ACK,” Molecular and Cellular Biology, vol. 30, no. 6, pp. 1541–1554, 2010.
[51]
A. R. Salomon, S. B. Ficarro, L. M. Brill et al., “Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 2, pp. 443–448, 2003.
[52]
N. Ibarrola, H. Molina, A. Iwahori, and A. Pandey, “A novel proteomic approach for specific identification of tyrosine kinase substrates using [ ]tyrosine,” Journal of Biological Chemistry, vol. 279, no. 16, pp. 15805–15813, 2004.
[53]
A. Wolf-Yadlin, N. Kumar, YI. Zhang et al., “Effects of HER2 overexpression on cell signaling networks governing proliferation and migration,” Molecular Systems Biology, vol. 2, article no. 54, 2006.
[54]
J. Rush, A. Moritz, K. A. Lee et al., “Immunoaffinity profiling of tyrosine phosphorylation in cancer cells,” Nature Biotechnology, vol. 23, no. 1, pp. 94–101, 2005.
[55]
C. Greenman, P. Stephens, R. Smith et al., “Patterns of somatic mutation in human cancer genomes,” Nature, vol. 446, no. 7132, pp. 153–158, 2007.
[56]
J. Kato, Y. Kaziro, and T. Satoh, “Activation of the guanine nucleotide exchange factor Dbl following ACK1-dependent tyrosine phosphorylation,” Biochemical and Biophysical Research Communications, vol. 268, no. 1, pp. 141–147, 2000.
[57]
N. P. Mahajan, Y. E. Whang, J. L. Mohler, and H. S. Earp, “Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor Wwox,” Cancer Research, vol. 65, no. 22, pp. 10514–10523, 2005.
[58]
V. Prieto-Echagüe, A. Gucwa, B. P. Craddock, D. A. Brown, and W. T. Miller, “Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1,” Journal of Biological Chemistry, vol. 285, no. 14, pp. 10605–10615, 2010.
[59]
J. C. Lougheed, R. H. Chen, P. Mak, and T. J. Stout, “Crystal structures of the phosphorylated and unphosphorylated kinase domains of the Cdc42-associated tyrosine kinase ACK1,” Journal of Biological Chemistry, vol. 279, no. 42, pp. 44039–44045, 2004.
[60]
H. R. Mott, D. Owen, D. Nietlispach et al., “Structure of the small G protein Cdc42 bound to the GTpase binding domain of ACK,” Nature, vol. 399, no. 6734, pp. 384–388, 1999.
[61]
N. Yokoyama and W. T. Miller, “Purification and enzyme activity of ACK1,” Methods in Enzymology, vol. 406, pp. 250–260, 2006.
[62]
N. Yokoyama, J. Lougheed, and W. T. Miller, “Phosphorylation of WASP by the Cdc42-associated kinase ACK1: dual hydroxyamino acid specificity in a tyrosine kinase,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 42219–42226, 2005.
[63]
M. C. Parrini, M. Lei, S. C. Harrison, and B. J. Mayer, “Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1,” Molecular Cell, vol. 9, no. 1, pp. 73–83, 2002.
[64]
V. Prieto-Echagüe, A. Gucwa, D. A. Brown, and W. T. Miller, “Regulation of Ack1 localization and activity by the amino-terminal SAM domain,” BMC Biochemistry, vol. 11, no. 1, 2010.
[65]
K. Mahajan and N. P. Mahajan, “Shepherding AKT and androgen receptor by Ack1 tyrosine kinase,” Journal of cellular physiology, vol. 224, no. 2, pp. 327–333, 2010.
[66]
M. S. A. Nur-E-Kamal, J. M. Kamal, M. M. Qureshi, and H. Maruta, “The CDC42-specific inhibitor derived from ACK-1 blocks v-Ha-Ras-indnced transformation,” Oncogene, vol. 18, no. 54, pp. 7787–7793, 1999.
[67]
A. Nur-E-Kamal, A. Zhang, S. M. Keenan et al., “Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells,” Molecular Cancer Research, vol. 3, no. 5, pp. 297–305, 2005.
[68]
N. P. Mahajan, Y. Liu, S. Majumder et al., “Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 20, pp. 8438–8443, 2007.
[69]
K. Mahajan, S. Challa, D. Coppola et al., “Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity,” Prostate, vol. 70, no. 12, pp. 1274–1285, 2010.
[70]
J. Li, U. Rix, B. Fang et al., “A chemical and phosphoproteomic characterization of dasatinib action in lung cancer,” Nature Chemical Biology, vol. 6, no. 4, pp. 291–299, 2010.
[71]
K. Mahajan, D. Coppola, S. Challa, et al., “Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation,” PLoS One, vol. 5, no. 3, article e9646, 2010.
[72]
T. Satoh, J. Kato, K. Nishida, and Y. Kaziro, “Tyrosine phosphorylation of ack in response to temperature shiftdown, hyperosmotic shock, and epidermal growth factor stimulation,” FEBS Letters, vol. 386, no. 2-3, pp. 230–234, 1996.
[73]
B. Nagar, O. Hantschel, M. A. Young et al., “Structural basis for the autoinhibition of c-Abl tyrosine kinase,” Cell, vol. 112, no. 6, pp. 859–871, 2003.
